Background. Haemolytic uraemic syndrome (HUS) is a disorder characterized by thrombotic microangiopathy, which is caused in 'typical forms' by gastrointestinal infections with Escherichia Coli species that produce verotoxins. Several studies have identified negative prognostic factors of the disease, among which prolonged oliguria, neurological involvement and increased leukocytosis have been more consistently reported. We have hypothesized that the genetic background may also predispose to the development of typical forms of HUS and may influence the clinical course of the disease. Methods. Fourteen polymorphisms, known to influence the coagulation pathway or the activity of the renin-angiotensin system, have been selected and studied in 150 Italian children with typical forms of HUS. Two hundred healthy Italian children were used as controls. Results. The risk of developing HUS was strongly associated with the platelet glycoprotein 1bα 145M allele (OR 3.08; CI: 1.62-5.85) (P < 0.001). A significant association was also found with polymorphisms located in the adipocyte-derived leucine aminopeptidase and factor V genes. A longer duration of dialysis was moderately associated with increased leukocytosis and with the 807T allele of the platelet glycoprotein 1a gene. High white blood cell count was also strongly associated with the risk of longterm sequelae (OR 2.91, CI: 1.21-6.98) (P < 0.02), whereas the 1166C allele of the angiotensin II type 1 receptor had a significant protective effect (OR 0.28, CI: 0.09-0.83) (P < 0.02).
Introduction
Haemolytic uraemic syndrome (HUS) is characterized by a thrombotic microangiopathy that involves primarily the renal capillaries and small arterioles [25] . Most cases are caused by gastrointestinal infections with Escherichia Coli species that produce verotoxins or Shiga toxins (VTEC) [13] .
Children with VTEC-associated HUS usually present with bloody diarrhoea, which is followed by clinical and biological symptoms related to thrombotic microangiopathy. These cases have been termed 'typical HUS' and are often labelled as 'VTEC(+)' and/or 'D(+)' forms.
In western countries, the prognosis of typical HUS has considerably improved during the past decades, with a mortality rate that has fallen well below 5% [6] . Among the 481 patients that were collected between 1988 and 2003 in the Italian HUS Surveillance Study for example, the mortality rate was 3.0% [7] . This progress is primarily related to the overall improvement in medical care, including the introduction of efficient dialysis techniques for small children.
Overall, complete recovery of renal function is reported in 65-80% of cases, while 10-30% of patients have chronic or end-stage renal failure (CRF/ESRF), hypertension or proteinuria at their follow-up evaluations (USA 1991 , Germany 1994 , Belgium 1994 , Italy 2005 . Differences between registry data are most likely related to differences in the time period of data collection and criteria for diagnosing long-term complications (in particular, hypertension and proteinuria). In the Italian HUS Surveillance Study, the cumulative incidence of ESRF was 3.6%, CRF was observed in 14% of cases and persistent hypertension was reported in 15% of patients at their long-term follow-up evaluation [7] .
Hence, despite major improvements in the treatment of typical HUS, a substantial percentage of patients do not fully recover. Several studies have tried to identify prognostic factors. Invariably, the briefness of the initial oliguric phase is the most reliable predictor of full recovery of renal function [6] . Several negative indicators have been less consistently identified. Among these, neurological involvement and increased leukocytosis at the onset of the disease are the most consistently reported negative risk factors [6] .
Herein, we have hypothesized that the genetic background may also influence the clinical course of typical forms of HUS. Based on the physiopathology of the disease, we have selected 14 gene polymorphisms that are known to influence the coagulation pathway and the reninangiotensin system (RAS) activities, and tested their influence on the probability of developing HUS and on the course of the disease.
Subjects and methods

Patient selection
All patients were recruited in the Italian HUS registry, which includes more than 500 records that have been collected since 1988. The registry contains clinical information on the acute phase of the illness as well as the follow-up data. In addition, as part of the registry, blood and stool samples have been collected for bacteriological, serological and genetic analyses.
For this study, all patients with typical HUS, defined by the presence of diarrhoea at the onset of the disease [D(+)] and/or by the demonstration of a VTEC infection [VTEC(+)] were selected. Positive VTEC infection was defined as a positive bacteriological and/or serological test, as previously detailed [7] . Briefly, bacteriological diagnosis required the demonstration of positive free faecal Shiga toxins or the isolation from faeces of E. Coli colonies that produce Shiga toxins. Serological diagnosis required positive ELISA identification of antibodies against one of the five major VTEC serogroups (O157, O26, O103, O111 and O145).
After identification of D(+) and/or VTEC(+) patients, only cases followed in paediatric nephrology centres involved in the present study and that had complete followup data were selected. To obtain homogeneous data, only patients that were evaluated at 1 year after the onset of the disease were selected. The follow-up data had to include information on the renal function, proteinuria and blood pressure. In the study period, the overall death rate was 3% [7] . No patient that died was included because informed consent and generally DNA were not available.
Significant proteinuria was defined as a urinary protein excretion >400 mg/24 h or a urine protein:creatinine ratio >0.5 (mg:mg). Hypertension was defined as a blood pressure measurement greater than the 90th percentile for age and height [27] on three repeated measurements or greater than the 90th percentile on a 24 h ambulatory blood pressure registration [4] or by the need of antihypertensive drugs. Chronic renal failure was defined as a creatinine clearance ≤75 ml/min/1.73 m 2 . Five different paediatric nephrology divisions have collaborated in this study and have recalled patients to collect blood samples and informed consents for the genetic analyses. Altogether, we were able to recruit 150 children with typical HUS.
Genotype determination
All polymorphisms were analysed in 120 patients, after obtaining informed consent. In the remaining 30 patients, not all genotypes could be defined because of insufficient DNA material, which could not be obtained again. These genetic data were compared with those obtained from 200 healthy paediatric Italian subjects, matched for gender.
Protocols used to characterize the various polymorphisms have been reported in addendum 1. Analysed polymorphisms are reported in Table 1 .
Techniques used for each polymorphism are very briefly summarized hereafter. Single nucleotide polymorphisms (SNPs) are indicated in the text as they are generally reported in the literature, with some alleles usually indicated by their amino acid and others by their nucleotide substitution.
Statistical analysis
Statistical analysis was performed using SPSS for Windows 8.0.0 software (SPSS Inc., Chicago, IL, USA).
Except for the GPIbα VNTR polymorphism, genotypes were analysed using recessive, dominant and addictive models. For each genotype, the reference allele used to define each model was the allele that is commonly designed as the 'wild type' and which has a 'protective' effect (e.g. the allele that has been associated in the literature with less hypertension and renal damage or with decreased risk of thrombosis, for RAS and coagulation genes, respectively). For space limitation, only the model with the highest statistical significance for each genotype is reported.
As the GPIbα VNTR polymorphism has four different allelic variants that correspond to different numbers of tandem repeats, it was tested using an addictive model. The addictive score of each genotype was calculated by summing the number of tandem repeats of each allele (e.g. D allele = 1, C allele = 2, B allele = 3 and A allele = 4).
Categorical data, including the Hardy-Weinberg equilibrium test, were compared using the Pearson chi-square test. The effect of independent variables on the duration of dialysis treatment was analysed by Cox-Mantel regression. The data were censured at 30 days of dialysis, as no patient needing dialysis for more than 30 days had recovered a normal renal function. No difference was made between peritoneal dialysis and haemodialysis treatments. For patients that did not undergo dialysis, their time of dialysis was indicated with a value of 0 days and included in the analysis. The effect of independent variables on the probability of long-term sequelae was analysed using logistic regression analysis. Univariate analysis was performed for each independent variable. Multivariate analysis was subsequently performed using variables that were associated with a P value < 0.10 at the univariate level. All analyses were controlled for a potential centre effect (not shown in the result tables).
Results are two-sided and considered significant at a P level < 0.05. Odds ratios (OR) and hazard ratios (HR) are reported with their 5% and 95% confidence intervals. Table 2 summarizes the clinical characteristics of patients recruited in the study.
Results
Patient characteristics
As shown, VTEC infection was demonstrated in approximately two-thirds of patients. In the remaining patients, tests were either not performed or were negative for a VTEC infection. In this later group, analyses were often incomplete (e.g. serology but no stool analysis or the reverse). More than 90% of patients had a prodromal diarrhoea.
Approximately one-fifth of patients had long-term renal sequelae at their 1-year follow-up. Of these, 10% had CRF (7 patients) or ESRF (8 patients). All patients that were still on dialysis after 30 days had CRF or ESRF at their 1-year follow-up evaluation.
Genotype distribution in the studied population
The RAS is a key determinant of renal glomerular function. Polymorphisms involving genes that encodes for proteins and enzymes that modulate its activity have been variably shown to be associated with the severity of renal diseases. Five of these were studied, including the ACE I/D, the AGT M235T, the AT1R 1166 A>C, the B2BKR I/D and ALAP 1583 A>G polymorphisms.
Based on the physiopathology of the thrombotic microangiopathy in typical HUS, nine polymorphisms of genes involved in the coagulation pathway were selected, including the PAI 5G/4G, the GPIa 807 C>T, the GPIIIa 1565 C >T, the FII 20210 G>A, the FV 1691 G>A, the MTHFR 677C>T and the GP1bα HPA 2 T145M, KOZAK −5 C>T and VNTR polymorphisms. As shown in Table 3 , all polymorphisms were in Hardy-Weinberg equilibrium in the studied population, with a trend towards unbalanced distributions for the ACE and GPIa polymorphisms.
Risk of disease
The effect of the above-listed genotypes on the risk of developing typical HUS was tested comparing the genotype distribution in the study population with the frequencies observed in 200 matched healthy individuals. As shown in Table 4 , the M allele of GP1bα HPA 2 polymorphism was significantly associated with a higher risk of developing a typical HUS (P < 0.001), with an odds ratio of 3.08 (CI: 1.62-5.85). The frequency of the M allele in the HUS population was 23% as opposed to 9% in the control population. Less significant associations were found with 
The 'reference allele' corresponds to the usually reported 'wild type' allele, which generally corresponds to the more frequent allele and to the allele with lower risks of thrombosis for the coagulation genes or linked to a lower activity of the renin-angiotensin system for the other genes. As the GP1bα VNTR genotype has four different alleles that correspond to the number of 39bp repeats, the sum of repeats between the maternal and paternal alleles were calculated and used assuming an addictive model of inheritance. the ALAP and FV genotypes. The A allele of FV, which is commonly regarded as a thrombotic risk factor, appears to have a protective effect. The frequency of this allele is however low (<10%), both in the general and in the typical HUS populations.
Severity of renal involvement during the acute phase
The initial severity of renal involvement was analysed by measuring the duration of the dialysis treatment. To correct for other confounding factors, non-genetic risk factors were also incorporated in the analysis, including gender, age, season of onset, white blood cell (WBC) count, occurrence of diarrhea and VTEC positivity. Overall, 73% of patients were treated with dialysis. The median duration of dialysis of the entire population, including patients that were not dialysed (time = 0 days), was 6 days (5-95% CI = 4-8 days). When only patients that were treated with dialysis were included in the analysis, the median time of treatment was 11 days (5-95% CI = 10-12 days). After 30 days, nine patients (6% of the entire population) were still on dialysis.
The results of the Cox-Mantel analysis are reported in Table 5 . By univariate analysis, high WBC count, the presence of diarrhoea and the T allele of the GPIa polymorphism were significantly associated with a prolonged dialysis treatment, whereas the C allele of the AT1R polymorphism had a significant protective effect. By multivariate analysis only the WBC count and the GPIa genotype retained statistical significance at the 0.05 levels. It should also be noticed that, whilst they were not significantly associated with the duration of renal replacement therapy, RAS gene polymorphisms showed a tendency towards a protective effect, as indicated by the hazard ratio < 1.
Long-term sequelae (1-year follow-up)
The analysis of long-term sequelae was limited to CRF/ESRF, persistent proteinuria or hypertension, at the 1-year follow-up evaluation. As already mentioned, 10% of patients did not recover a normal renal function, seven of which had ESRF ( Table 2 ). The analysis of independent risk factors for the development of any of the above sequelae is reported in Table 6 . By univariate analysis, WBC count and the AT1R, PAI and GPIa genotypes were associated with a worse outcome. By multivariate analysis, high WBC count at the onset of the disease was highly associated with a less favourable outcome, while the C allele of the AT1R polymorphism had a protective effect. WBC count [OR 3.47 (1.35-8.87), P < 0.01] and the C allele of the AT1R polymorphism [OR 0.21 (0.04-0.98) -P < 0.05] were also found to be significant risk factors when the analysis was restricted only to the risk of CRF or ESRF. Of the 15 patients who had CRF or ESRF, two (13%) carried the AT1R C allele, as compared to 50% in patients with normal renal function after 1 year (P < 0.02).
Discussion
Despite major progress that has been made in the management of patients with HUS, a significant number do not recover completely and have long-term sequelae [6] .
Reported risk factors of poor outcome include biological indicators of the severity of the initial illness, such as WBC count, platelet count, anaemia, creatinine clearance, C-reactive protein and circulating cytokine levels, neurological involvement, duration of oliguria, hypertension, age, gender, VTEC positivity, the occurrence of a prodromal diarrhoea, the pathology of renal lesions and the season of onset. Overall, prolonged oliguria, neurological involvement and increased leukocytosis are the most frequently reported negative prognostic factors [6] .
Bacteriological and epidemiological investigations of outbreaks of HUS have also shown that not all children infected with VTEC species develop HUS. In fact, a very significant number of children remain symptom-free or develop a self-limiting gastrointestinal illness, suggesting that the toxin load and other unidentified individual factors also play a role in the development of thrombotic microangiopathy [9] . In the present work, we have hypothesized that the genetic background may play a predisposing role in the development of the disease and may influence the outcome of typical forms of HUS.
Based on the physiopathology of the VTEC-related typical disease, we have chosen to screen polymorphisms of genes that modulate the coagulation pathway or regulate the RAS, as these have been shown to modulate the activity of angiotensin II and have been variably associated with the progression of renal failure in glomerular renal diseases [11, 15] . Most of the analysed RAS polymorphisms are well known, with the exception of the ALAP gene, also termed ERAP1, PILS-AP, ARTS-1. The ALAP gene encodes a type II integral transmembrane aminopeptidases that, among other functions, inactives angiotensin II playing at Pennsylvania State University on April 29, 2014 http://ndt.oxfordjournals.org/ Downloaded from Variables that were significant at the 0.1 level in the univariate analysis were evaluated by multivariate analysis. Data were corrected for a potential centre effect (not shown). Variables and alleles to which the odds ratios refer are specified in the 'reference' column. Significant results are highlighted in bold.
a role in blood pressure regulation [30, 31] . In the past decade, several genes that regulate the alternative complement pathway and VWF polymerization have been shown to cause atypical forms of HUS [5] . Polymorphic variants of these genes, not studied in the present work, may also constitute potential risk factors for typical forms of HUS. The factors that strengthen the association of a clinical condition with a given genetic polymorphism include the magnitude and homogeneity of the studied population, the statistical power of the association, the number of covariates that have been included in the analysis and experimental evidence supporting the association.
We have analysed a homogenous group of patients who have been recruited over a period of nearly 15 years. The majority had prodromal diarrhoea and proven VTEC infection. In VTEC-negative or unknown patients, we have considered the presence of a prodromal diarrhoea a reliable indicator of typical HUS, as other forms of HUS are not commonly associated with gastrointestinal symptoms. This approach is validated by the multivariate analysis data showing that VTEC negativity was not associated with a worse outcome, as it would be expected if these patients had atypical forms of HUS.
The most significant result of this study was the association of HUS with the GP1bα HPA2 T145M polymorphism. This strong association was characterized by a substantial enrichment of the M allele in the HUS population and is supported by pathophysiological and experimental evidence. Hence, after Shiga toxin binding to its globotriaosylceramide receptor, glomerular endothelial cells secrete unusually large multimers of VWF, which triggers the adhesion of activated platelets by means of the GP1bα [12, 16] . The importance of the GP1bα-VWF interaction has also been documented in shear-stress experiments [19] . The HPA-2 polymorphism corresponds to the human platelet antigen-2 allelic system and influence the VWF-GP1bα interaction. In vitro studies have shown that botrocetin-induced VWF-GP1bα binding is significantly more pronounced in platelets harbouring the 'b' antigen that corresponds to the M145 allele [26] . In humans, the GP1bα HPA2 T145M polymorphism has been shown to be associated with coronary artery disease in patients aged ≤ 60 years [17] , and with dengue haemorrhagic fever and shock syndrome that shares several pathophysiological features with HUS [24] .
HUS patients were also found to carry more often the less active ALAP 1583 GG genotype [8] . This enzyme has multiple biological activities that are influenced by the 1583 A>G SNP and involve trimming of intracellular and extracellular proteins [10] . In this respect, it is interesting to observe that Shiga toxin 1 and 2 sub-units need to be activated by partial proteolysis in order to inhibit protein synthesis [16] . Unexpectedly, the Factor V 1691A allele, which is generally viewed as a thrombogenic allele [21] , was found to be protective against the development of HUS. As this allele is uncommon in the Italian population, the clinical relevance of this finding is uncertain.
In respect to the severity of the disease and the risk of long-term sequelae, our results are the opposite of our initial hypothesis. As shown in Tables 5 and 6 , odds ratios of most RAS alleles that have been correlated to higher angiotensin II activity were skewed towards a protective effect (odds ratio < 1).
Only the AT1R 1166C allele, however, was strongly protective against the risk of long-term sequelae. This allele has been shown to be associated with increased incidence of essential hypertension and to mediate in vitro a higher response to angiotensin II [28] . This unexpected finding is at the moment poorly substantiated by experimental evidence. Renin activity has been reported to be lower than in the normal population during the active phase of HUS and does not correlate with blood pressure levels or with the outcome [20] . In fact, it has recently been shown that AT1R stimulation enhances tissue factor production in Shigatoxin 2 stimulated human glomerular endothelial cells [18] . Hypothetically, the haemodynamic effects of angiotensin II may predominate in the acute phase of the disease and preserve renal perfusion in vessels partially obstructed by the thrombotic microangiopathy. In addition, the protective role of the AT1R 1166C allele could also be related to its proliferative action on endothelial cells [14] , which may counteract the pro-apoptotic stimuli of Shiga toxins on endothelial cells [2] .
Increased leukocytosis was clearly associated with more severe disease and with worse outcome. This result has already been reported by others [1, 3, 22, 23, 29] , but is at odds with our previous report on a larger group of patients from the same registry [7] . The most likely explanation for this discrepancy is that the present sub-group of patients was more homogeneous, containing only typical cases of HUS, whereas the larger database of the Italian registry contains all forms of HUS, including a substantial number of D(−) VTEC (−) patients [7] .
In conclusion, we have shown that the GP1bα HPA2 genotype is strongly associated with the risk of developing typical forms of HUS. This may have important implications in the evaluation outbreaks of HUS and underlines the importance of the interaction of VWF with GP1bα in the pathophysiology of the disease. This interaction may constitute a valid target for therapeutic interventions. In addition, our results suggest that AT1 receptor-mediated angiotensin II activity may have a beneficial role in promoting early renal recovery. In light of these results, and until further information is available, agents that block the RAS, such as
